Annals of internal medicine
-
COVID-19, the illness caused by SARS-CoV-2, became a worldwide pandemic in 2020. Initial clinical manifestations range from asymptomatic infection to mild upper respiratory illness but may progress to pulmonary involvement with hypoxemia and, in some cases, multiorgan involvement, shock, and death. ⋯ Antiviral treatment and immunomodulators have been shown to benefit certain patients. This article summarizes current recommendations on prevention, diagnosis, management, and treatment of COVID-19.
-
Comment Randomized Controlled Trial
Cytisinicline increased smoking abstinence at 6 and 12 wk.
Rigotti NA, Benowitz NL, Prochaska J, et al. Cytisinicline for smoking cessation: a randomized clinical trial. JAMA. 2023;330:152-160. 37432430.
-
Comment Randomized Controlled Trial
In healthy older adults, low-dose aspirin increased incident anemia at a median 4.7 y.
McQuilten ZK, Thao LT, Pasricha SR, et al. Effect of low-dose aspirin versus placebo on incidence of anemia in the elderly: a secondary analysis of the Aspirin in Reducing Events in the Elderly trial. Ann Intern Med. 2023;176:913-921. 37335992.
-
Xylazine is an animal sedative, approved by the U. S. ⋯ Clinical experience along with the available pertinent research were used to review xylazine adulteration of the drug supply and provide guidance on the care of patients exposed to xylazine. This review discusses xylazine pharmacology, animal and human clinical effects, and what is known to date about care of patients experiencing acute overdose, xylazine-fentanyl withdrawal, and xylazine-associated wounds.
-
Evening chronotype may promote adherence to an unhealthy lifestyle and increase type 2 diabetes risk. ⋯ National Institutes of Health.